Clincosm LogoSign in Get a demo

stage iva oropharyngeal squamous cell carcinoma ajcc v7

Showing 1 - 8 of 8
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III

Recruiting
  • Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma
  • +16 more
  • Birmingham, Alabama
  • +289 more
Jan 31, 2023

Active, not recruiting
  • Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
  • +8 more
  • Cetuximab
  • +3 more
  • Pittsburgh, Pennsylvania
    University of Pittsburgh Cancer Institute (UPCI)
Jan 26, 2023

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive)

Recruiting
  • Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • +10 more
  • Intensity-Modulated Radiation Therapy
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 8, 2022

Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell

Active, not recruiting
  • Head and Neck Carcinoma of Unknown Primary
  • +19 more
  • Duarte, California
  • +18 more
Aug 24, 2022

Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB

Recruiting
  • Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
  • +2 more
  • Intensity-Modulated Radiation Therapy
  • +4 more
  • Birmingham, Alabama
  • +21 more
May 13, 2022

CDKN2A-p16 Positive, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell

Recruiting
  • CDKN2A-p16 Positive
  • +5 more
  • Tucson, Arizona
    The University of Arizona Medical Center-University Campus
Mar 7, 2022

Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage

Completed
  • Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7
  • +2 more
  • Durvalumab
  • Tremelimumab
  • Houston, Texas
    M D Anderson Cancer Center
Mar 16, 2021

Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma Trial

Completed
  • Recurrent Colon Carcinoma
  • +41 more
  • Cetuximab
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Mar 12, 2020